Catheter Precision (VTAK) Ends ATM Equity Offering, Raises $36.5 Million

Catheter Precision, Inc. (NYSE American: VTAK) recently made a significant announcement regarding the termination of its at-the-market (ATM) equity offering program. In a strategic move to secure funding for growth, the company successfully completed a financing transaction with institutional investors amounting to a substantial $36.5 million. This decision was aimed at fortifying the company’s financial position and bolstering its balance sheet to support future expansion and initiatives.

The termination of the ATM equity offering program signifies a simplification of the company’s capital structure, eliminating any financial burdens associated with legacy financing. Additionally, securing a substantial amount of capital from strategic institutional investors provides Catheter Precision with the necessary resources to accelerate growth and explore new avenues for expansion. The conversion of short-term notes to long-term liabilities further enhances the company’s liquidity and financial stability, setting the stage for sustained growth in the future.

David Jenkins, the CEO and Chairman of VTAK, expressed his confidence in the restructuring efforts, highlighting the positive impact on the company’s financial stability and strategic direction. By aligning with long-term institutional partners, Catheter Precision aims to instill investor confidence in its growth trajectory and value creation strategy. The restructuring and realignment of financial resources position the company to pursue growth opportunities with renewed vigor and focus.

The strategic institutional investment not only provides Catheter Precision with the necessary financial flexibility to advance key growth initiatives but also allows for the scaling of multiple business opportunities and expansion of market presence. By strengthening its financial position and aligning with long-term partners, the company is well-positioned to drive significant shareholder value through disciplined growth and execution.

It is important to note that this press release does not constitute an offer to sell or solicit securities. Investors are encouraged to refer to the Company’s filings with the Securities and Exchange Commission for detailed information regarding the transaction. Catheter Precision remains committed to developing innovative solutions for the treatment of cardiac arrhythmias and is dedicated to bringing new technologies to market through collaboration with physicians and ongoing product innovation.

In conclusion, the recent financing and balance sheet restructuring undertaken by Catheter Precision demonstrate the company’s commitment to long-term growth and value creation. With a strengthened financial position and strategic alignment with institutional partners, the company is poised to embark on a new phase of growth and innovation in the field of advanced electrophysiology solutions.